



Deposited via The University of York.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/191230/>

Version: Published Version

Article:

Naznin, Baby, Quayyum, Zahidul, Tajree, Jannatun et al. (2022) Assessment of Public-Private Partnership (PPP) Models in Health Systems in Least Developed, Low Income and Lower-Middle-Income Countries and Territories:A Protocol for a Systematic Review. Health Care: Current Reviews. ISSN: 2375-4273

<https://doi.org/10.35248/2375-4273.22.10.306>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Additional File 2: Reporting checklist for protocol of a systematic review

		Reporting Item	Page Number
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	NA
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1-2
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	8-9
	#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Sources	#5a	Indicate sources of financial or other support for the review	9
Sponsor	#5b	Provide name for the review funder and / or sponsor	9
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	9
Rationale	#6	Describe the rationale for the review in the context of what is already known	3
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5-7
Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	4-5
Study records - data management	#11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Study records - data collection process	#11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
Data items	#12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplification	7
Outcomes and prioritization	#13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5-6
Risk of bias in individual studies	#14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	7

Correspondence to: Baby Naznin, Department of Public Health, BRAC University, Dhaka, Bangladesh. E-mail: baby.naznin@bracu.ac.bd

Received: 30-Aug-2022, Manuscript No. HCCR-22-17911; **Editor assigned:** 02-Sep-2022, Pre QC No. HCCR-22-17911(PQ); **Reviewed:** 16-Sep-2022, QC No. HCCR-22-17911; **Revised:** 22-Sep-2022, Manuscript No. HCCR-22-17911(R); **Published:** 29-Sep-2022, DOI: 10.35248/2684-1320.22.10.306

Citation: Naznin B, Quayyum Z, Tajree J, Golder S, Ebenso B, Barua D, et al. (2022) Assessment of Public-Private Partnership (PPP) Models in Health Systems in Least Developed, Low Income and Lower-Middle-Income Countries and Territories: A Protocol for a Systematic Review. Health Care Curr Rev. 10:306

Copyright: © 2022 Naznin B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

	#15a	Describe criteria under which study data will be quantitatively synthesised	07-Aug
Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	7-8
	#15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	NA
	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8
Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	NA
Confidence in cumulative evidence	#17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	7-8